Resurgent Financial Advisors LLC Gilead Sciences, Inc. Transaction History

Resurgent Financial Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$73.27 - $83.09 $19,270 - $21,852	263 Added 12.27%	2,407 $194,000
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $5,841 - $6,372	79 Added 3.83%	2,144 $160,000
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $3,648 - $4,161	-48 Reduced 2.27%	2,065 $159,000
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $163,510 - $186,289	-2,115 Reduced 50.02%	2,113 $175,000
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $14,645 - $21,025	-235 Reduced 5.27%	4,228 $362,000
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $68,411 - $78,143	1,149 Added 34.67%	4,463 $276,000
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $89,985 - $101,350	-1,559 Reduced 31.99%	3,314 $205,000
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $282,244 - $353,682	4,873 New	4,873 $289,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Resurgent Financial Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Resurgent Financial Advisors LLC with notifications on news.